An alluring combination of platform and pipeline brought multiple would-be partners to Morphotek Inc.'s table before Eisai Co. Ltd. opted for an outright $325 million buyout. Nicholas Nicolaides, CEO of Exton, Pa.-based Morphotek, said he expects the merger to finish in four to six weeks, and Eisai, of Tokyo, plans to leave Morphotek intact as a free-standing concern, with no layoffs. (BioWorld Today) Read More
